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Pro-Invasive Activity of the Hippo Pathway Effectors
YAP and TAZ in Cutaneous Melanoma
Flore Nallet-Staub1,2,3, Ve´ronique Marsaud1,2,3, Ling Li4, Criste`le Gilbert1,2,3, Sophie Dodier1,2,3,
Ve´ronique Bataille5, Marius Sudol6, Meenhard Herlyn4 and Alain Mauviel1,2,3
YAP and its paralog protein TAZ are downstream effectors of the Hippo pathway. Both are amplified in many
human cancers and promote cell proliferation and epithelial–mesenchymal transition. Little is known about the
status of the Hippo pathway in cutaneous melanoma. We profiled Hippo pathway component expression in a
panel of human melanoma cell lines and melanocytic lesions, and characterized the capacity of YAP and TAZ to
control melanoma cell behavior. YAP and TAZ immuno-staining in human samples revealed mixed cytoplasmic and
nuclear staining for both proteins in benign nevi and superficial spreading melanoma. TAZ was expressed at higher
levels than YAP1/2 in all cell lines and in those with high invasive potential. Stable YAP or TAZ knockdown
dramatically reduced the expression of the classical Hippo target CCN2/connective-tissue growth factor (CTGF),
as well as anchorage-independent growth, capacity to invade Matrigel, and ability form lung metastases in mice
following tail-vein injection. YAP knockdown also reduced invasion in a model of skin reconstruct. Inversely, YAP
overexpression increased melanoma cell invasiveness, associated with increased TEA domain–dependent trans-
cription and CCN2/CTGF expression. Together, these results demonstrate that both YAP and TAZ contribute to the
invasive and metastatic capacity of melanoma cells and may represent worthy targets for therapeutic intervention.
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INTRODUCTION
Components of the Hippo pathway were initially identified in
Drosophila in which a strong overgrowth phenotype was
shared by pathway mutants (Staley and Irvine, 2012). Hippo
pathway components are highly conserved and are often
found mutated or expressed at lower levels in a variety of
cancers (Zhao et al., 2008a; Bao et al., 2011; Chan et al.,
2011; Yin and Zhang, 2011; Varelas and Wrana, 2012).
The Hippo suppressor pathway consists of a cascade of
kinases, MST and LATS in mammals, that phosphorylate the
effector proteins YAP and TAZ, thereby controlling their
nucleo-cytoplasmic localization and functions. MST1/2
phosphorylate and activate the kinases LATS1/2. The latter
phosphorylate YAP and TAZ, leading to their cytoplasmic
retention by 14-3-3 proteins (Mauviel et al., 2012).
Inactivation of the MST and LATS kinases results in nuclear
accumulation of YAP and TAZ and subsequent activation of
target genes, many of them involved in cell proliferation.
Complex cell membrane-associated signals upstream of the
Hippo kinases involve numerous proteins such as Merlin and
Kibra, the protocadherin FAT4, the cell polarity-associated
Crumbs complex (review in Grusche et al. (2010)), and the
adherens junction protein a-catenin (Schlegelmilch et al.,
2011).
There are two main YAP isoforms, YAP1 and YAP2, also
called YAP1-1 and YAP1-2, each existing as four isoforms, and
one TAZ molecule. All three contain WW domain(s) and an
SH3 domain-binding motif, as well as a PDZ-binding motif
in their C-terminus (Gaffney et al., 2012). YAP1 and YAP2
contain a proline-rich N-terminal sequence not present in TAZ
and differ from each other by their number of WW domains:
YAP1, like TAZ, contains one WW domain, whereas YAP2
has two. WW domain proteins have the property to bind other
partners that exhibit proline-rich modules named PY motifs
(reviewed in Sudol et al. (2001)).
The primary partners of YAP and TAZ in the cell nucleus are
TEA domain (TEAD) transcription factors, for which they
function as transcriptional co-activators. Knockdown experi-
ments in mice have shown that a number of phenotypes
associated with disruption of the Hippo pathway may be
recapitulated by alteration of TEAD function. A classical target
gene associated with YAP/TAZ-regulated TEAD-dependent
transcription is CCN2, which encodes connective-tissue
growth factor (CTGF), a secreted factor implicated in tumor
progression (reviewed in de Winter et al. (2008) and Dhar and
Ray (2010)). YAP/TAZ interact with other transcription factors,
such as SMADs, RUNX2, and p73 (for review, see Sudol
(2010) and Mauviel et al. (2012)).
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Alterations in the expression and function of upstream
components of the Hippo pathway in human cancers, together
with functional studies in vitro and in mice, point to a tumor
suppressor role of the Hippo pathway. For example, over-
expression in mammary epithelial cells of YAP/TAZ mutants
that cannot be phosphorylated, and are therefore exclusively
nuclear, leads to cell transformation and acquisition of
tumorigenic potential associated with their binding to TEAD
transcription factors (Chan et al., 2011; Yin and Zhang, 2011).
Conditional and simultaneous knockout of Mst1/2 and YAP
overexpression in mouse liver both result in the development
of hepatocarcinomas (Liu et al., 2012). YAP and TAZ are
expressed at high levels with strong nuclear localization in
a number of cancers, and their oncogenic potential is often
associated with their interactions with TEADs and WW
domain-binding proteins (reviewed in Zeng and Hong
(2008); Pan (2010); and Sudol et al. (2012)). Conversely,
expression of LATS and MST is often reduced in cancer,
possibly via hypermethylation of their gene promoters
(reviewed in Hergovich (2012)). Noteworthy, both TAZ and
YAP expression in mammary epithelial tumor cells contribute
to their metastatic properties associated with expression of
epithelial-to-mesenchymal transition (markers; Overholtzer
et al., 2006; Chan et al., 2008).
To date, little is known about the role of Hippo signaling
and its effectors YAP and TAZ in cutaneous melanoma
biology. In this work, using both cell-based assays and tumor
xenograft experiments in mice, we undertook an in-depth
analysis of the expression, activation status, and function of
YAP and TAZ in melanoma.
RESULTS
Expression profiles of Hippo pathway members in human
melanoma cell lines
The expression of Hippo pathway effector molecules YAP1,
YAP2, and TAZ in a panel of 12 human melanoma cell lines
and 4 distinct normal human melanocyte cultures was mea-
sured by quantitative reverse transcriptase–PCR (Figure 1a).
Levels of these three transcripts were highly variable across the
panel. TAZ was expressed at levels 5–10 times higher than
those for YAP2, itself at levels 10–20 times higher than YAP1.
YAP1 and YAP2 were expressed at similar low levels in
both normal human epidermal melanocytes and melanoma
cell lines. Noticeably, expression of TAZ was higher in all
melanoma cell lines compared with melanocytes, except in
the MNT1 cell line that expressed the lowest levels of TAZ
among melanoma lines. MNT1 cells are non-tumorigenic after
sub-cutaneous injection in mice under conditions whereby all
other cell lines form tumors (Moore et al., 2004).
Four melanoma cell lines were selected for subsequent
determination of YAP and TAZ protein levels. 1205Lu and
WM852 were the two cell lines of the panel with the highest
expression of TAZ, whereas the SKmel28 and 501mel cell
lines express TAZ at lower levels. 1205Lu and WM852 cell
lines are the more aggressive, when compared in either
Matrigel invasion assays or in a model of experimental bone
metastasis in mice (Javelaud et al., 2007; Alexaki et al., 2010;
Mohammad et al., 2011). Western analysis revealed higher
TAZ and YAP protein levels in 1205Lu and WM852 cells
compared with SKmel28 and 501mel cells (Figure 1b), con-
sistent with the gene expression profiles. Phosphorylated TAZ
and YAP were detected in all cell lines, with slightly higher
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Figure 1. YAP and TAZ expression in a series of human melanoma cell lines
and normal human neonatal melanocytes (NHEMs). (a) Quantitative reverse
transcriptase–PCR analysis of YAP1, YAP2, and TAZ expression in a panel of
12 human melanoma cell lines (gray) and normal human neonatal melanocyte
(black) cultures from four distinct donors, normalized against GAPDH.
(b) Western analysis of YAP, TAZ, and phospho-YAP/TAZ protein levels in
1205Lu, WM852, SKmel28, and 501mel human melanoma cell lines. Note
that anti-P-TAZ detection required film exposure 5 longer than for other
antibodies.
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phospho-TAZ levels in SKmel28 and 501mel cells compared
with 1205Lu and WM852 cells.
Consistent with the presence of P-YAP/TAZ in melanoma
cell lines, Hippo pathway kinases MST and LATS were
expressed in all cell lines: MST1 and MST2 were expressed
at similar levels within a given cell line, yet at variable
levels and degree of phosphorylation across cell lines
(Supplementary Figures S1A and S1B online, respectively).
LATS2 was expressed at levels 5–10 times higher than LATS1.
Merlin/NF2 expression was also highly variable across cell
lines (Supplementary Figure S1A online).
Immunofluorescent staining of proliferating 1205Lu mela-
noma cells confirmed that most YAP and TAZ protein is
nuclear, whereas a small proportion is cytoplasmic Supple-
mentary Figure S1C online). As expected, P-YAP/TAZ were
exclusively cytoplasmic (Supplementary Figure S1C online),
consistent with a partial constitutive activation of the pathway,
as already suggested by P-YAP/TAZ levels detected by western
blotting (see above). As all melanoma cell lines except WM852
(11/12) carry an activating mutation on the BRAF gene, we
conclude that the expression pattern of Hippo pathway mem-
bers is independent from the BRAF mutational status.
YAP and TAZ expression in human melanocytic lesions
To our knowledge, there has been no analysis of Hippo
signaling effector molecules in human melanocytic lesions
published to date. We thus examined the expression of YAP
and TAZ by immunohistochemistry in a series of clinical
samples, including benign nevi (n¼8) and superficial spread-
ing melanoma (n¼29). Representative images are shown in
Figure 2. Blinded analysis by a professional dermato-pathologist
found no significant differences in the staining of TAZ and YAP
between benign and malignant melanocytic lesions. We did
not find any trend in the positivity or distribution of both
antibodies according to Breslow thickness. When positive in
melanocytes, all other cells including keratinocytes and stromal
cells stained positive for both antibodies as well. TAZ and YAP
were distributed either in the nucleus or cytoplasm or both,
but YAP was more often distributed in the cytoplasm.
YAP and TAZ knockdown specifically inhibit melanoma cell
tumorigenicity and invasiveness, not proliferation, in vitro
To determine whether there is a causal relationship between
YAP/TAZ expression and melanoma cell behavior, we per-
formed lentivirus-driven, small hairpin RNA-mediated stable
knockdown of YAP1/2 or TAZ in 1205Lu, WM852, SKmel28,
and 501mel melanoma cell lines. Efficacy and specificity of
each knockdown was verified by quantitative PCR (Supple-
mentary Figure S2A online) and western blotting (Figure 3a and
Supplementary Figure S2B online). No obvious modification of
cell morphology or population doubling times was observed
after either knockdown when compared with mock-infected
cells (Supplementary Figure S2C and S2D online, respectively).
Cell cycle analysis determined by flow cytometry after BrdU
incorporation showed no changes in the relative proportion of
cells in G1, S, and G2/M phases upon either YAP or TAZ
knockdown (not shown). Likewise, small interfering RNA
(siRNA)-mediated YAP or TAZ knockdown showed high
efficacy and specificity in 1205Lu and SK28 melanoma cells
(Supplementary Figures S3A and S3B online), without affecting
cell proliferation (Supplementary Figure S3C online).
To determine whether YAP and TAZ contribute to the
tumorigenicity of melanoma cells, we first performed ancho-
rage-independent growth assays on soft agar. As shown
in Figure 3b (left panels and corresponding histograms), both
YAP and TAZ knockdown reduced the number of colonies
formed by 1205Lu cells by 30–50%. In SKmel28 cells, YAP
knockdown had a strong inhibitory activity, whereas TAZ
knockdown had limited effects (Figure 3b, right panels and
histograms).
Both YAP and TAZ stable knockdown efficiently reduced the
propensity of 1205Lu (Figure 3c, left panel) and SKmel28 (right
panel) cells to invade Matrigel. Similar results were obtained
after siRNA-mediated YAP and TAZ knockdown (Supple-
mentary Figure S3D online, left panels). Simultaneous YAP/
TAZ siRNA knockdown was not more efficient than either single
knockdown (Supplementary Figure S3D online, right panels).
In a skin reconstruct model, shYAP-transduced 1205Lu
melanoma cells, identified as S100-positive cells in 6-mm thick
histological sections, did not migrate as deep into the dermis
as control shRNA (shCTL)-transduced cells (Figure 3d online).
Also, the number of cells that transmigrated from the epidermal
compartment to the dermis was dramatically lower after YAP
knockdown.
YAP and TAZ knockdown inhibits melanoma lung metastasis in
mice
Next, we determined whether YAP and TAZ are implicated
in the capacity of 1205Lu melanoma cells to form lung
metastases following tail-vein injection in mice. Forty-five
days later, mice were killed when the first signs of distress
were noticed in shCTL-injected group. Macroscopic examina-
tion of lungs revealed massive development of metastases in
five out of six mice from the shCTL group, whereas metastases
were found in the lungs of only two out of six and one out of
six mice inoculated with shYAP and shTAZ cells, respectively
(Figure 4a). The latter was dramatically smaller in size than
those observed in the two former groups. Histological analysis
confirmed these post-autopsy observations and indicated a
drastic reduction in total metastasis area per lung in shYAP
and shTAZ groups compared with the shCTL group
(Figure 4b). Thus, YAP and TAZ knockdown reduce both the
incidence and the growth of lung metastases by intravenously
inoculated 1205Lu melanoma cells.
YAP overexpression enhances the clonogenic potential and
invasive capacity of melanoma cells in vitro
We next generated clones of 1205Lu and SKmel28 melanoma
cells overexpressing YAP, as verified by quantitative PCR
(Supplementary Figure S4A online) and western blotting
(Figure 5a). No modification of cell morphology (Supple-
mentary Figure S4B online) or growth rate was observed in
either cell line upon YAP overexpression (Supplementary
Figure S4C online), consistent with the knockdown data,
which also did not show modifications of cell growth
(see Supplementary Figure S2C and D online).
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YAP overexpression did not significantly increase the capacity
of 1205Lu cells to grow as clones on agar (Figure 5b, left panels
and histograms), whereas markedly increasing SKmel28 ancho-
rage-independent growth (Figure 5b, right panels and histo-
grams). It is possible that 1205Lu cells, which express a lot more
TAZ than SKmel28 cells (see Figure 1), may be less responsive to
forced YAP overexpression, as these proteins have been known
to be functionally redundant in certain situations (Mauviel et al.,
2012). In fact, although both cells lines exhibited increased
invasive capacity in a Matrigel assay upon YAP overexpression,
the effect was markedly higher in SKmel28 compared
with 1205Lu cells (Figure 5c right versus left panel, respectively),
consistent with their lower levels of endogenous YAP/TAZ.
Altering YAP and TAZ levels modifies TEAD-dependent
transcription and CCN2/CTGF expression in 1205Lu
melanoma cells
To gain insight into the molecular mechanisms underlying
forced alteration of YAP and TAZ expression, we focused our
attention on the modulation of CTGF, a canonical YAP/TAZ
target (Zhang et al., 2009) that contributes to metastasis both
in melanoma and breast cancer (Kang et al., 2003;
Mohammad et al., 2011). CTGF is encoded by CCN2, a
TEAD transcription factor gene target (Zhang et al., 2009) for
which YAP and TAZ function as transcriptional co-activators
(Vassilev et al., 2001). Stable YAP and TAZ knockdown in
1205Lu cells reduced CCN2 mRNA steady-state levels
(Figure 6a, left panel), whereas YAP overexpression did the
opposite (right panel). CCN2 gene modulation was transcrip-
tional as CCN2 promoter activity showed parallel modulation
upon YAP/TAZ knockdown or YAP overexpression (Figure 6b).
TEAD-specific transcription followed the same modulation
(Figure 6c). TAZ knockdown was consistently more efficient
than YAP knockdown in regulating CCN2 expression and
TEAD-dependent transcription, likely reflecting the higher
expression levels of TAZ versus YAP in melanoma cells (see
Figure 1). Also, YAP and TAZ mutants with an exclusive
nuclear localization (YAP5SA and TAZS89A) efficiently
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Figure 2. Detection of YAP and TAZ proteins in human melanocytic lesions by immunohistochemistry. Representative staining for YAP and TAZ by
immunohistochemistry in a series of benign nevi and superficial spreading melanoma (SSM). S100 staining of an adjacent slide served to identify cells
of melanocytic origin in tissue. Note the presence of both cytoplasmic and nuclear YAP and TAZ in both types of melanocytic lesions. (a) Bar¼24mm,
(b) bar¼12mm.
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enhanced TEAD-specific transcription, whereas YAPS94A,
incapable of binding TEADs, and the exclusively cytoplasmic
mutant TAZD393 did not (Figure 6d).
In SKmel28 cells, YAP and TAZ knockdown had little effect
on CCN2 expression, promoter activity, and TEAD-specific
transcription (Supplementary Figure S5A–C online), whereas
YAP overexpression increased CCN2 expression and promoter
activity, as well as TEAD-specific transcription (Supplementary
Figure S5D–F online). Overexpression of nuclear mutants of
YAP and TAZ (YAP5SA and TAZS89A) dramatically increased
TEAD-dependent transcription, whereas cytoplasmic mutants
YAPS94A and TAZD393 did not (Supplementary Figure S5G
online). Reduced CCN2 expression upon siRNA-mediated
knockdown of YAP and TAZ, either alone or in combination,
occurred in 1205Lu, not SKmel28 melanoma cells (Supplemen-
tary Figure S6 online), consistent with the lower levels of expre-
ssion of YAP and TAZ in SKmel28 compared with 1205Lu cells.
These data provide direct evidence for the dependence of
TEAD-dependent transcription and target gene expression with
YAP and TAZ expression levels in melanoma cells. How this
relates to their invasive and metastatic capacity remains to be
determined.
1205Lu
0
15
30
45
60
sh
CT
L
sh
YA
P
sh
TA
Z
Co
lo
ny
 n
um
be
r
**
***
sh
CT
L
sh
YA
P
sh
TA
Z
SKmel28
0
30
60
90
120
sh
CT
L
sh
YA
P
sh
TA
Z
**
In
va
di
ng
 c
el
ls
0
40
80
120
160
sh
CT
L
sh
YA
P
sh
TA
Z
1205Lu
**
***
0
15
30
45
60
sh
CT
L
sh
YA
P
sh
TA
Z
SKmel28
***
***
UKHC
YAP
TAZ
sh
CT
L
sh
YA
P
sh
TA
Z
sh
CT
L
sh
YA
P
sh
TA
Z
1205Lu SKmel28
H
&S
S1
00
Ki
67
shYAPshCTL
Ce
ll i
nv
as
io
n 
(μm
)
0
50
100
150
200
shCTL shYAP
250
300
350
400
*****
*
* 
*
****
0
25
50
75
shCTL shYAP
Ki
67
-p
os
itiv
e 
ce
lls
 (%
)
Figure 3. YAP1/2 or TAZ knockdown inhibits melanoma cell tumorigenicity in vitro. 1205Lu and SKmel28 melanoma cell lines were infected with
lentiviruses expressing either YAP1/2 or TAZ small hairpin RNA. (a) Western analysis of YAP and TAZ protein levels in shCTL-, shYAP-, and shTAZ-transduced 1205Lu
(left) and SKmel28 (right) melanoma cell lines. (b) Representative fields of a clonogenic assay on soft agar. (c) Matrigel invasion assay. Results, expressed as number
of invading cells, are the mean±SEM of three independent experiments. *Po0.05, **Po0.001, ***Po0.0001. (d) shCTL- and shYAP-transduced 1205Lu melanoma
cells were incorporated into skin reconstructs (see Materials and Methods). At day 18, the latter were harvested and embedded into paraffin. 5mm parallel sections
were stained with hematoxylin and eosin, S-100 antibody, and Ki67. Representative images (upper panel) are shown. Bar¼ 50mm. Invasion depth (lower left
panel) was measured in eight random fields of each of the skin reconstructs using Image J software, with the dermo-epidermal junction as a starting point. Data are
presented as whisker plots. The median value is indicated as horizontal bar surrounded by upper and lower quartiles. Outliers are indicated by asterisks. The
percentage of KI67-positive melanoma cells (lower right panel) was calculated in eight random fields, in relation to S100 positivity in parallel histological sections.
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DISCUSSION
Overexpression of YAP and TAZ induces cell transformation
and tumor-forming ability in mammary epithelial cells
(Overholtzer et al., 2006; Dong et al., 2007; Chan et al.,
2008), because of their capacity to interact with, and function
as transcriptional co-activators of, the TEAD family of
transcription factors (Zhao et al., 2008b; Chan et al., 2009;
Zhang et al., 2009). YAP overexpression in mouse livers
results in hepatocellular carcinomas (Zhou et al., 2009; Lu
et al., 2010; Song et al., 2010), and a wide range of cancers
displays high levels of TAZ or YAP expression (reviewed in
Zhao et al. (2010)). In this report, we provide evidence for
active Hippo signaling in both benign and malignant
melanocytic lesions and in melanoma cell lines, with both
proteins localized both in the cytoplasm and in the nucleus.
We also provide evidence that endogenous YAP/TAZ
contribute to the metastatic behavior of melanoma cells, as
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Figure 4. YAP and TAZ knockdown inhibit lung metastasis following tail-vein
injection in nude mice. (a) Representative macroscopic images of lungs from
6-week-old female nude mice, 45 days after tail-vein injection of 4 105
mock-, shYAP-, or shTAZ-1205Lu cells. Histograms represent the % of mice
bearing metastases in each group. (b) Representative lung sections.
Bar¼125mm. M, metastasis.
Figure 5. YAP2 overexpression in 1205Lu and SKmel28 melanoma cell
lines enhances their clonogenic and invasive potential in vitro. 1205Lu (left)
or SKmel28 (right) melanoma cells were stably transfected with either empty
pEGFP or YAP2 expression vectors. (a) Western blot validation of YAP
overexpression in melanoma cell clones. (b) Soft agar clonogenic assay.
Representative fields are shown. Results are expressed as mean±SEM of
three independent experiments, each performed with triplicate dishes.
(c) Matrigel invasion assay. The number of invading cells was counted using
bright-field microscopy after staining colonies with crystal violet, 24 hours
(1205Lu) or 48 hours (SKmel28) later. Results are expressed as mean±SEM
of three independent experiments. **Po0.001, ***Po0.0001.
pE
G
FP
C1
9-
YA
P2
C2
0-
YA
P2
0
20
40
60
80
pE
G
FP
C1
9-
YA
P2
C2
0-
YA
P2
Co
lo
ny
 n
um
be
r
pE
G
FP
C1
-Y
AP
2
C5
-Y
AP
2
Co
lo
ny
 n
um
be
r
pE
G
FP
C1
-Y
AP
2
C5
-Y
AP
20
35
70
105
***
***
0
200
400
600
pE
G
FP
C1
9-
YA
P2
C2
0-
YA
P2
In
va
di
ng
 c
el
ls
0
15
30
45
60
pE
G
FP
C1
-Y
AP
2
C5
-Y
AP
2
**
**
In
va
di
ng
 c
el
ls
pE
G
FP
C1
9-
YA
P2
C2
0-
YA
P2
1205Lu
YAP
UKHC
pE
G
FP
C1
-Y
AP
2
C5
-Y
AP
2
SKmel28
140
F Nallet-Staub et al.
The Hippo Pathway in Melanoma
128 Journal of Investigative Dermatology
specific knockdown of either of these Hippo effectors lead to
reduced clonogenic and invasive capacity in vitro, and
reduced their propensity to metastasize to lungs following
tail-vein injection in nude mice. Inversely, YAP/TAZ over-
expression increased anchorage-independent growth and
invasion into Matrigel, thus identifying a direct role for
endogenous YAP and TAZ in controlling melanoma cell
metastatic potential. Consistent with our observations, it was
recently found that overexpression of a mutant YAP with
exclusive nuclear localization enhances the metastatic poten-
tial of the 4T1 mammary carcinoma cell line, as well as that of
the A375 melanoma cell line (Lamar et al., 2012). In the latter
study, based solely on overexpression approaches, the authors
concluded that YAP–TEAD interactions were necessary for the
pro-metastatic activity of YAP. Our data are consistent with
their conclusion, yet bring important information about the
role of Hippo effectors in melanoma biology. Although Lamar
et al. (2012) only examined the effects of overexpression of
mutant forms of YAP with altered functional domains in one
melanoma cell line and one breast carcinoma cell line, they
did not examine TAZ function. We chose a broader approach,
which consisted in profiling human melanocytic lesions and
melanoma cell lines for endogenous YAP and TAZ expression,
followed by thorough mechanistic analysis of the respective
roles played by endogenous YAP or TAZ in melanoma cell
behavior. As TAZ is expressed at much higher levels than both
YAP isoforms in melanoma cells (see Figure 1), TAZ knock-
down was more potent in inhibiting melanoma cell invasive
and metastatic capacities than YAP knockdown (Figures 3 and
4). Yet, in agreement with the data by Lamar et al. (2012),
overexpression of wild-type YAP enhanced the invasive
capacity of melanoma cells, associated with increased
TEAD-dependent transcription and CCN2 expression (Figures
5 and 6). Thus, despite active Hippo signaling, as evidenced
by the detection of cytoplasmic, phosphorylated YAP and TAZ
in melanoma cells, the nuclear functions of YAP and TAZ are
enhanced by overexpression of wild-type proteins. Our knock-
down approach allowed, to our knowledge previously unre-
ported demonstration for a role of endogenous YAP/TAZ in
melanoma cell behavior, and suggest that YAP and TAZ may
be important targets for therapeutic intervention. From our
data herein and those by Lamar et al. (2012), it appears that
disrupting or antagonizing their capacity to enhance TEAD
transcriptional activity, and possibly that of other signaling
pathways known to promote melanoma metastasis, including
transforming growth factor-b and WNT/b-catenin signaling
(Ferrigno et al., 2002; Javelaud et al., 2007, 2008; Mohammad
et al., 2011; Mauviel et al., 2012), is likely to negatively affect
melanoma cell invasiveness and capacity to metastasize. In
this respect, the aromatic heterocyclic small-molecule verte-
porfin was recently found to disrupt YAP-TEAD interactions
(Liu-Chittenden et al., 2012). This molecule, known
commercially as Visudyne (Novartis International AG, Basel,
Switzerland), is approved by the FDA for photodynamic
therapy of neovascular macular degeneration (Michels and
Schmidt-Erfurth, 2001). Based upon these findings, it will be
interesting to test the capacity of verteporfin to interfere with
melanoma cell invasive properties.
0.000
0.004
0.008
0.012
sh
CT
L
sh
YA
P
sh
TA
Z
8X
G
TI
I l
uc
ife
ra
se
 a
ct
iv
ity
*
***
0.000
0.005
0.010
0.015
pE
G
FP
C1
9-
YA
P2
C2
0-
YA
P2
*** ***
8X
G
TI
I l
uc
ife
ra
se
 a
ct
iv
ity
CC
N2
/G
AP
DH
 m
RN
A
0
50
100
150
200
250
sh
CT
L
sh
YA
P
sh
TA
Z
***
**
0
20
40
60
80
sh
CT
L
sh
YA
P
sh
TA
Z
CC
N2
 p
ro
m
ot
er
 a
ct
ivi
ty **
***
0
500
1,000
1,500
2,000
pE
G
FP
C1
9-
YA
P2
C2
0-
YA
P2
***
*
CC
N2
/G
AP
DH
 m
RN
A
0
30
60
90
120
pE
G
FP
C1
9-
YA
P2
C2
0-
YA
P2
***
***
CC
N2
 p
ro
m
ot
er
 a
ct
ivi
ty
8X
G
TI
I l
uc
ife
ra
se
 a
ct
iv
ity
0
1
2
3
4
5
pc
DN
A
YA
P5
SA
YA
PS
94
A
TA
ZS
89
A
TA
ZΔ
39
3
6
**
***
Figure 6. CCN2 expression and TEAD-dependent transcription levels are
proportional to YAP and TAZ levels in 1205Lu melanoma cells. Quantitative
reverse transcriptase–PCR analysis of CCN2 expression normalized against
GAPDH (a), CCN2 promoter activity (b), and TEAD-specific transcription (c) in
1205Lu melanoma cells after either stable knockdown (left panels) of YAP or
TAZ or YAP overexpression (right panels). (d) Effects of various YAP and TAZ
mutants on TEAD-specific transcription in 1205Lu melanoma cells: YAP5SA
and TAZS89A are exclusively nuclear; TAZD393 is exclusively cytoplasmic;
YAPS94A is unable to bind TEADs. In panels b–d, Renilla was used as a
control for transfection efficiency. Results are mean±SEM of three
independent experiments using triplicate dishes. *Po0.05, **Po0.001,
***Po0.0001. TEAD, TEA domain.
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We did not observe any significant effect of the modulation
of YAP/TAZ expression on the proliferative capacity of
melanoma cells, either after knockdown or overexpression.
All melanoma cell lines used in our studies carry the
BRAFV600E mutation, except for the WM852 cell line that
carries the NRASQ61K mutation. These oncogenic mutations,
found in a large percentage of melanoma tumors (Chin et al.,
2006), result in active MEK/ERK signaling and have an
important role in promoting melanoma cell proliferation
(Chin et al., 2006). Our data suggest that the roles played by
BRAFV600E and NRASQ61K as drivers of melanoma cell growth
are not significantly affected by YAP/TAZ levels.
To conclude, this report provides comprehensive profiling of
YAP/TAZ expression and function in melanoma: YAP and TAZ
were detected in both benign nevi and metastatic melanoma
with similar distribution and expression levels. Thus, we could
not establish any prognostic value for either YAP or TAZ. Yet,
from our functional studies, it appears that YAP and TAZ Hippo
effector molecules are important players controlling the inva-
sive and metastatic potential of melanoma cells.
MATERIALS AND METHODS
Cell culture
All human melanoma cell lines have been described previously (Rodeck
et al., 1999; Javelaud et al., 2007; Alexaki et al., 2008, 2010; Javelaud
et al., 2011). They all carry an activating mutation (V600E) of the BRAF
gene, except for the WM852 cell line, which carries an activating
mutation of NRAS (Q61K). They all were grown in RPMI 1640
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum
and antibiotics, at 37 1C, 5% CO2 in a humidified atmosphere. Primary
human melanocytes from neonatal foreskins were obtained from four
distinct Caucasian individuals, and grown in modified MCDB medium
(GIBCO, Invitrogen), as described previously (Busca et al., 2005).
Immunohistochemistry and human tissues
Paraffin-embedded pathological samples from human melanocytic
lesions were obtained from the pathology archives of the National Health
Services (West Hertfordshire Hospitals NHS Trust, Herts, UK). All speci-
mens were re-evaluated by an expert pathologist. Tissues were obtained
according to local ethical guidelines and approved by the local ethics
committee. Five-mm sections were de-waxed and rehydrated through
graded alcohol baths. After antigen retrieval (20minutes at 95 1C) in
citrate buffer, pH 6.0, tissue sections were preincubated for 30minutes
with 20% horse serum, then incubated with antibodies directed against
YAP (sc-15407, 1:200, 1hour at room temperature), TAZ (sc-17130,
1:200, overnight at 4 1C), or S100 (Dako France SAS, Trappes, France,
Z0311 1:1000, 1hour at room temperature). A Vectastain ABC kit (Vector
Laboratories, Burlingame, CA) was used as biotinylated secondary anti-
body. Counterstaining was performed with hematoxylin.
Cell proliferation assays
Human melanoma cells were seeded in six-well culture plates. Every
other day, cells were trypsinized and enumerated using a Coulter
Counter (Beckman Coulter, Fullerton, CA).
Cells transfections
For reporter assays, melanoma cells were seeded in 24-well
plates and transfected at 70–80% confluency in fresh medium with
the polycationic compound FuGENE (Roche Diagnostics, Indianapolis,
IN). Cells were transfected with 200 ng of firefly luciferase promoter
reporter construct, CCN2-luc or (8XGTII)2-luc ((Ota and Sasaki, 2008;
Zhang et al., 2009), kind gifts from Kun-Liang Guan, UCSD, La Jolla,
CA, and Hiroshi Sasaki, Kumamoto University, Japan, respectively),
together with 50 ng of expression vectors, pcDNA, YAP5SA, YAPS94A
((Zhang et al., 2009), gifts from K.-L. Guan), TAZS89A or TAZD393
((Varelas et al., 2008), gifts from Jeffrey Wrana, University of Toronto,
ON, Canada). Fifty nanogram of Renilla luciferase expression vector
was co-transfected to estimate transfection efficiencies. After
incubation, luciferase activities were determined with a Dual-Glo
luciferase assay kit (Promega, Madison, WI) using a Fluoroskan Ascent
FL (Thermo Labsystems, Courtaboeuf, France). All experiments were
performed at least three times.
For stable YAP overexpression, melanoma cells in 100-mm
diameter culture dishes were transfected with 10mg of either empty
pEGFP or the same vector-expressing YAP (Basu et al., 2003). Three
days later, G418 (Sigma-Aldrich, St Louis, MO, 0.7 g ml 1) was
added to the culture medium. Selection of stably transfected clones
occurred over a 3-week period. For transient, acute YAP and TAZ
silencing, subconfluent melanoma cells were transfected with two
distinct siRNAs targeting either YAP or TAZ (Sigma-Aldrich human
YAP or TAZ Mission siRNAs 1 and 2, respectively) using HiperFect
(Qiagen, Courtaboeuf, France). Two non-targeting siRNAs (Sigma-
Aldrich Mission Universal Negative control siRNAs 1 and 2) were
used as controls. For stable YAP or TAZ gene silencing, subconfluent
human melanoma cells were infected in 96-well dishes with
lentiviral particles that expressed a control, non-targeting,
scrambled small hairpin RNA sequence or three distinct target-
specific constructs that encode 19–25 nt (plus hairpin) small hairpin
RNA to knock down YAP1/2 or TAZ expression (Santa Cruz
Biotechnology, Santa-Cruz, CA, sc-108080, sc-38637-V and sc-
38568-V, respectively), in the presence of 4mg ml 1 polybrene.
Stably transduced cell populations were selected with puromycin
(2mg ml 1). Reverse transcriptase–PCR was used to verify YAP
expression after each passage and before new experiments.
RNA extraction and gene expression analysis
Total RNA was isolated from cell cultures using a NucleoSpin RNA
kit (Macherey-Nagel, Du¨ren, Germany). Genomic DNA contami-
nation was eliminated by DNase I treatment. One microgram of RNA
was reverse transcribed using a Thermoscript kit (Invitrogen).
cDNAs were processed for real-time reverse transcriptase–PCR using
SYBR Green technology in a 7900 Real-Time PCR System (Applied
Biosystems, Foster City, CA). Reactions were carried out for 40 cycles
(95 1C for 15 seconds and 60 1C for 1 minute) after an initial
10-minute incubation at 95 1C. Data were analyzed using Applied
Biosystems Sequence Detection Software (version 1.2.1) and normal-
ized to GAPDH expression. Experiments were performed in tripli-
cate to validate gene expression data in each cell line. Primers
are: GAPDH, forward (F): 50-TGGGTGTGAACCATGAGAAGT
ATG-30, reverse (R), 50-GGTGCAGGAGGCATTGCT-30; MERLIN,
F: 50-TGAACGCACGAGGGATGAGTTG-30, R: 50-GCCTTTTCAGCCA
ACAGGTCAG-30; LATS1, F: 50-CACTGGCTTCAGATGGACACAC-30,
R: 50-GGCTTCAGTCTGTCTCCACATC-30; LATS2, F: 50-GTTCTTCAT
GGAGCAGCACGTG-30, R: 50-CTGGTAGAGGATCTTCCGCATC-30;
MST1, F: 50-CTGTGTAGCAGACATCTGGTCC-30, R: 50-CTGGTTTT
CGGAATGTGGGAGG-30; MST2 F: 50-GGCAGATTTTGGAGTGG
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CTGGT-30, R: 50-AATGCCAAGGGACCAGATGTCG-30; YAP1, F: 50-
GTGAGCCCACAGGAGTTAGC-30, R: 50-CTCGAGAGTGATAGGTG
CCA-30; YAP2, F: 50-TCTTCCTGATGGATGGGAAC-30, R: 50-GGCTG
TTTCACTGGAGCACT-30; TAZ, F: 50-GTATCCCAGCCAAATCTCG-30,
R: 50-TTCTGAGTGGGGTGGTTC-30; CCN2, F: 50-TGCACCGCCAAA
GATGGT-30, R: 50-GACTCTCCGCTGCGGTACAC-30.
Western blotting
Whole-cell extracts were prepared on ice in 50 mM Tris pH
7.5, 150 mM NaCl, 0.5% NP40, 20mM phenylmethylsulfonyl
fluoride and protease inhibitor cocktail for 10 minutes. Debris were
removed by centrifugation. Protein concentration was assayed
with a one-step colorimetric method (Bio-Rad protein reagent; Bio-
Rad, Hercules, CA), and 35mg of protein were resolved by SDS-
PAGE and transferred to Hybond ECL nitrocellulose filters (Amersham
Biosciences, Glattburgg, Switzerland). Filters were placed in blocking
solution (1 Tris-buffered saline, 5% nonfat milk) for 1 hour
and immunoblotted with either rabbit anti-YAP (Santa Cruz Bio-
technology, sc-15407), rabbit anti-phospho-YAP (Cell Signaling Tech-
nology, Danvers, MA, #4911), rabbit anti-TAZ (Cell Signaling Technol-
ogy, #4883) rabbit anti-phospho-TAZ (sc-17610), rabbit anti-MERLIN
(sc-332) rabbit anti-LATS1 (sc-28223), rabbit anti-phospho-LATS1 (Cell
Signaling Technology, #9157), rabbit anti-MST2 (Cell Signaling Tech-
nology, #3952), rabbit anti-phospho-MST1/2 (Cell Signaling Technol-
ogy, #3681), at a 1:1,000 dilution in 1 Tris-buffered saline, 0.1%
Tween-20, and 5% nonfat milk, overnight at 4 1C. A goat anti-UKHC
(sc-13356) antibody was used as a control. For detection of phos-
phorylated proteins, BSA replaced nonfat milk. Filters were then
washed and incubated with horseradish peroxidase-conjugated sec-
ondary antibodies (rabbit or goat, Santa Cruz Biotechnology) for
2 hours. Filters were washed, developed, and revealed according to
chemiluminescence protocols (ECL; Amersham Biosciences).
Invasion assays
Tissue culture Transwell inserts (8mm pore size; Falcon, Franklin
Lakes, NJ) were coated for 3 hours with 10mg (1205Lu and WM852)
or 5mg (SKmel28 and 501mel) of Matrigel (Biocoat, BD Biosciences,
San Jose, CA) in 100ml of phosphate-buffered saline at 37 1C. After
air-drying the chambers for 16 hours, the Matrigel barrier was
reconstituted with 100ml Dulbecco’s minimal essential medium for
24 hours at 37 1C. The chambers were then placed into 24-well dishes
containing 500ml of RPMI medium supplemented with 1% fetal calf
serum. 5 104 melanoma cells were added to the upper well of each
chamber in 250ml of serum-free RPMI medium. After a 24-hour
(1205Lu and WM852) or a 48-hour (SKmel28 and 501mel) incuba-
tion period, invading cells were counted by bright field microscopy at
 200 in six random fields. Additional details of the procedure may
be found in Alexaki et al. (2010). Experiments were performed at least
three times, each with triplicate samples.
Anchorage-independent growth
Mock-, YAP-, and TAZ-knockdown melanoma cells (1 104 or
2 104) resuspended in RPMI 1640 medium containing 0.3% agar
(Sigma-Aldrich) and supplemented with 10% fetal calf serum were
seeded into six-well plates on top of a 0.6% soft agar bed in similar
medium. Cultures were maintained for 28 days and the total number
of colonies in each well was determined using a phase contrast
microscope (Nikon France, Rollay, France). Results are expressed as
the mean±SEM of three independent experiments performed with
triplicate dishes.
Human skin reconstructs
Human skin reconstructs were generated as described previously (Li
et al., 2011). Briefly, dermal reconstructs consisted of bovine type I
collagen contracted for 4 days with embedded dermal fibroblasts
(7.5 104 per dish) before seeding control shCTL, or shYAP-infected
1205Lu cells (0.83 105) together with keratinocytes (4.17 105) on
top of the dermal reconstructs over an 4-day period in skin reconstruct
medium before air exposure until day 18 to allow epidermal
differentiation. At that point, skin reconstructs were harvested and
fixed in 10% neutral buffered formalin for 2–3 hours, processed by
routine histological methods, embedded into paraffin, sectioned
(5mm), then stained with an S-100 antibody (1:1,000, 30 minutes at
room temperature (Z0311, DAKO, Les Ulis, France)) to identify cells of
melanocytic origin, and with Ki67 (ready to use, 1 hour at room tempe-
rature, (08-0156 Life technologies) as a marker of cell proliferation.
Experimental lung metastasis in nude mice
Female 6-week-old Swiss nu/nu (nude) mice (Janvier, Le-Genest-
Saint-Isle, France) were housed at the animal facility of the Curie
Institute, under pathogen-free conditions. Their care was in accor-
dance with the principles of the Declaration of Helsinki Principles
and with the institutional guidelines of the French Ethical Committee
(Ministe`re de l’Agriculture et de la Foreˆt, Direction de la Sante´ et de la
Protection Animale, Paris, France). Experiments were performed
under supervision of authorized investigators. shCTL, shYAP, or
shTAZ 1205Lu melanoma cells in logarithmic growth phase
(4 105/200ml phosphate-buffered saline) were slowly injected into
the tail vein. Mice were killed 45 days later, as the first signs of
distress were noticed. Lungs were rapidly excised and dissected,
photographed, and fixed in paraformaldehyde (Sigma-Aldrich) for
further immunohistochemical analysis.
Statistical analyses
Differences between groups were determined by one-way analysis of
variance followed by Bonferroni’s posttest. All data were analyzed
using GraphPad Prism v6.0 software (GraphPad Software, La Jolla,
CA), and expressed as mean±SEM. Statistical significance was set at
Po0.05.
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